Cancer Metabolism: A Modeling Perspective by Ghaffari, Pouyan et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Nov 08, 2017
Cancer Metabolism: A Modeling Perspective
Ghaffari, Pouyan; Mardinoglu, Adil; Nielsen, Jens
Published in:
Frontiers in Physiology
Link to article, DOI:
10.3389/fphys.2015.00382
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Ghaffari, P., Mardinoglu, A., & Nielsen, J. (2015). Cancer Metabolism: A Modeling Perspective. Frontiers in
Physiology, 6, [382]. DOI: 10.3389/fphys.2015.00382
REVIEW
published: 16 December 2015
doi: 10.3389/fphys.2015.00382
Frontiers in Physiology | www.frontiersin.org 1 December 2015 | Volume 6 | Article 382
Edited by:
Radhakrishnan Nagarajan,
University of Kentucky, USA
Reviewed by:
Osbaldo Resendis-Antonio,
Instituto Nacional de Medicina
Genomica, Mexico
Preetam Ghosh,
Virginia Commonwealth University,
USA
*Correspondence:
Jens Nielsen
nielsenj@chalmers.se
Specialty section:
This article was submitted to
Systems Biology,
a section of the journal
Frontiers in Physiology
Received: 23 September 2015
Accepted: 24 November 2015
Published: 16 December 2015
Citation:
Ghaffari P, Mardinoglu A and Nielsen J
(2015) Cancer Metabolism: A
Modeling Perspective.
Front. Physiol. 6:382.
doi: 10.3389/fphys.2015.00382
Cancer Metabolism: A Modeling
Perspective
Pouyan Ghaffari 1, Adil Mardinoglu 1, 2 and Jens Nielsen 1, 2, 3*
1Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden, 2 Science for
Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden, 3Novo Nordisk Foundation Center for
Biosustainability, Technical University of Denmark, Hørsholm, Denmark
Tumor cells alter their metabolism to maintain unregulated cellular proliferation and
survival, but this transformation leaves them reliant on constant supply of nutrients
and energy. In addition to the widely studied dysregulated glucose metabolism to
fuel tumor cell growth, accumulating evidences suggest that utilization of amino acids
and lipids contributes significantly to cancer cell metabolism. Also recent progresses
in our understanding of carcinogenesis have revealed that cancer is a complex
disease and cannot be understood through simple investigation of genetic mutations
of cancerous cells. Cancer cells present in complex tumor tissues communicate with
the surrounding microenvironment and develop traits which promote their growth,
survival, and metastasis. Decoding the full scope and targeting dysregulated metabolic
pathways that support neoplastic transformations and their preservation requires both
the advancement of experimental technologies for more comprehensive measurement
of omics as well as the advancement of robust computational methods for accurate
analysis of the generated data. Here, we review cancer-associated reprogramming of
metabolism and highlight the capability of genome-scalemetabolic modeling approaches
in perceiving a system-level perspective of cancer metabolism and in detecting novel
selective drug targets.
Keywords: cancer metabolism, metabolic modeling, systems biology, systemsmedicine, genome scale metabolic
reconstruction, metabolic networks and pathways, tumor metabolism
INTRODUCTION
The past decades has seen a dramatic expansion in investigations on mechanism of cancer related
metabolic adaptations, and this has resulted in accumulated evidences suggesting considerable
association between several pathways in humanmetabolism andmalignant transformation (Vander
Heiden et al., 2009; Cairns et al., 2011; Schulze and Harris, 2012). Recently, the state of “deregulated
cellular metabolism” was added by Hanahan and Weinberg as one of the hallmarks of cancer
(Hanahan and Weinberg, 2000), reflecting the overall consensus around the idea of altered cellular
metabolism through neoplastic progression (Hanahan and Weinberg, 2011). Consistent with this
approach, investigation of cancer-associated metabolic alterations attracted considerable effort and
resulted in successful identification of several selectivemetabolic targets that started to enter clinical
trials (Vander Heiden, 2011; Galluzzi et al., 2013). Activation of oncogenes and deactivation of
tumor suppressor genes, have been linked to cancer-associated metabolic reprogramming (Levine
and Puzio-Kuter, 2010). Also, accumulation of metabolites such as 2-hydroxyglutarate, fumarate,
and succinate has been proposed to drive oncogenesis, due to disruption in enzymatic activity of
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isocitrate dehydrogenase (IDH), fumarate hydratase (FH), and
succinate dehydrogenase (SDH), respectively (Isaacs et al., 2005;
Selak et al., 2005; Dang et al., 2010). Additionally, some agents
that conventionally have been used in cancer treatment–such
as gemcitabine, 5-fluourouracil and methotrexate—are in fact
metabolic enzyme inhibitors (Chabner and Roberts, 2005). In
line with these findings, accumulated evidences from recent
epidemiological studies supported influence of whole-body
metabolism on tumor progression and drug response (Vander
Heiden et al., 2009; Vander Heiden, 2011; Galluzzi et al., 2013).
High-throughput omics technologies experienced a dramatic
breakthrough during the last decade enabling simultaneous
measurement of interacting molecular components in context of
complex cellular structure and characterization of transformed
cellular processes at genome-scale. Accumulation of DNA,
microRNA and protein expression measurements, along with
more detailed metabolomics data, has revealed a broader view
on cancer-associated metabolic shifts. The more advanced
understanding of molecular and genetic events underlying
neoplastic transformation acquired, the more complex portrait
of tumor metabolism has emerged. Today, analyzing multi-
layer data generated via high-throughput technologies and
integrating them into a descriptive unified model is a nontrivial
challenge. Computational methods, capable of processing and
integrating multi-dimensional data, have been employed in
investigation of metabolic states in health and disease, and in
identification of new selective targets and biomarkers. Here, we
will review current knowledge in cancer metabolism, underlining
capabilities of genome-wide metabolic models in opening new
therapeutic windows.
FUELS FOR CANCER CELLS
One of the best known features of most tumor cells is utilizing
high amounts of glucose and metabolizing it differently from
normal cells, converting pyruvate derived from glucose to lactate
in the cytosol and secreting it rather than oxidizing pyruvate
in mitochondria. Normal cells principally elevate conversion of
glucose to lactate in hypoxic conditions, whereas this phenotype
is common in transformed cancer cells even when oxygen is
abundant, a phenotype first described by Otto Warburg more
than fifty years ago and referred to as “The Warburg effect”
or aerobic glycolysis (Warburg, 1956). Glycolysis can produce
ATP faster but far less efficient than oxidative phosphorylation.
This shift makes tumor cells to be dependent on high rate of
glucose consumption to meet their biosynthesis, energy, and
redox requirements (Semenza et al., 2001; Cairns et al., 2011).
This metabolic phenotype of cancer cells, dramatic increase in
glucose uptake, has been studied extensively and used clinically in
cancer diagnosis to visualize tumors by 2-deoxy-2-[fluorine-18]
fluoro-D-glucose positron emission tomography (18F-FDG PET;
Som et al., 1980; Kelloff et al., 2005).
Elevated glycolytic flux promotes shunting of compounds
into branched metabolic pathways to synthesis macromolecules
needed for proliferation (Cairns et al., 2011). Downstream flux
of glycolysis intermediates into oxidative and non-oxidative
arms of the pentose phosphate pathway (PPP) produces
ribose-5-phosphate and NADPH, two essential components
for tumor cell growth. Ribose-5-phosphate is a precursor for
nucleotide synthesis and NADPH is required to handle redox
stress (Lunt and Vander Heiden, 2011; Dang, 2012). Another
branched pathway from glycolysis is serine biosynthesis, which
is important for nucleotide, amino acid, and lipid biosynthesis
(Lunt and Vander Heiden, 2011). Sustained proliferation of
some melanoma and breast cancer cells has been associated to
amplification of phosphoglycerate dehydrogenase (PHGDH), the
enzyme catalyzing the first step of serine biosynthesis (Locasale
et al., 2011; Possemato et al., 2011). Furthermore, the metastasis
of breast cancer cell has been associated with the up-regulation
of the serine biosynthesis pathway (Possemato et al., 2011;
Figure 1).
Glutamine plays a key role in sustaining rapid cell
proliferation (Jain et al., 2012). Glutamine is the most abundant
amino acid in culture media (Eagle et al., 1956) and plasma
(Stein and Moore, 1954) and seems to be in excess relative
to required amounts for protein and nucleotide synthesis
(DeBerardinis et al., 2007). Tumor cells experiencing aerobic
glycolysis need glutamine carbon to replenish TCA cycle
intermediates and sustain enhanced biosynthetic metabolism
to support cell proliferation (DeBerardinis et al., 2007; Lunt
and Vander Heiden, 2011; Mullen et al., 2012). Glutamine is
also a primary source of nitrogen for the cell (DeBerardinis
et al., 2007). Under hypoxic conditions, glutamine can undergo
reductive deamination to generate alpha-ketoglutrate and
consequently oxaloacetate, pyruvate, and acetyl-CoA to sustain
anabolic metabolism (Mullen et al., 2012). Although most cell
culture-based studies of cancer metabolism have focused on the
utilization and fate of glucose and glutamine, tumor cells in vivo
have access to other sources of nutrients, like amino acids, to
sustain the elevated proliferation rate. Measuring consumption
and release profiles of metabolites from the NCI-60 panel of cell
lines identified high correlation between glycine consumption
and cancer cells proliferation rates (Jain et al., 2012). Exogenous
serine uptake rate increases dramatically in tumor cells and
deprivation of serine acts as a trigger to activate serine synthesis
pathway and rapid inhibition of aerobic glycolysis, which
results in an increased flux to the TCA cycle (Maddocks et al.,
2012). Glycine and serine can be inter-converted by serine
hydroxymethyltransferase (SHMT) and be used for one-carbon
metabolism and nucleotide synthesis (Labuschagne et al., 2014;
Boroughs and DeBerardinis, 2015). The directionality of this
inter-conversion has critical effect on cancer cell proliferation.
Exogenous serine can be used both for protein biosynthesis and
it can be converted to glycine and one-carbon units needed for de
novo nucleotide biosynthesis, whereas exogenous glycine cannot
compensate for nucleotide synthesis (Labuschagne et al., 2014).
These findings may reflect the fact that tumor cell proliferation
is supported by serine rather than glycine. Glycolysis also plays
an essential role for nucleotide biosynthesis (Lunt et al., 2015)
and understanding relative consumption rate of exogenous
amino acids compared to glucose-derived serine and glycine in
transformed cells will be important.
In addition to glutamine, serine and glycine, other amino acids
may also contribute to cancer cell proliferation. Branched-chain
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FIGURE 1 | Overview of cancer-associated metabolic pathways. The main metabolic pathways that contributes to malignancy and offer potential drug targets
are illustrated. Metabolic enzymes that have been associated with tumor initiation and growth are marked in red. GLUT1, glucose transporter; HK, hexokinase; 6PGD,
6-Phosphogluconate dehydrogenase; PFKFB3, 6-phosphofructo-2-kinase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; PHGDH, phosphoglycerate
dehydrogenase; PGAM1, Phosphoglycerate mutase 1; PKM, Pyruvate kinase; LDHA, lactate dehydrogenase A; MCT, Monocarboxylate transporter; PDH, Pyruvate
dehydrogenase; CPT1, Carnitine palmitoyltransferase I; FASN, fatty acid synthase; RNR, ribonucleotide reductase; FH, fumarate hydratase; SDH, succinate
dehydrogenase; IDH, isocitrate dehydrogenase; GLUD, glutamate dehydrogenase; GLS1, glutaminase 1; ASCT2, Amino-acid transporter 2; ACLY, ATP citrate lyase;
ACC, acetyl-CoA carboxylase; ACSS2, Acetyl CoA synthetase2; DHFR, DHF reductase; TYMS, thymidylate synthase; HMGCR, HMG-CoA reductase; CK, choline
kinase; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; PRPP, 5-phospho-alpha-D-ribose 1-diphosphate; IMP, inosine monophosphate; UMP, uridine
monophosphate; dNTP, deoxynucleotide triphosphate; G3P, glyceraldehyde 3-phosphate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP,
phosphoenolpyruvate; OAA, Oxaloacetate; AKG, α-ketoglutarate; HMG-CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A; THF, tetrahydrofolate; 5,10 mTHF,
5,10-methylene tetrahydrofolate; DHF, dihydrofolate.
amino acids (BCAAs) are abundant amino acids in plasma (Stein
and Moore, 1954; Meister, 1965), and growth of wild type IDH
glioma, subgroup of brain tumors with poorest clinical treatment,
is highly associated with expression of branched-chain amino
acid transaminase 1 (BCAT1; Yan et al., 2009; Tönjes et al.,
2013). Metabolomics profiling of patient-derived glioma samples
also suggested correlation between increasing tumor grade and
cysteine catabolism (Prabhu et al., 2014). Although, the current
state of investigations suggest that amino acids primarily are
used for protein synthesis in proliferating cells (Dolfi et al., 2013;
Zhang et al., 2014), whereas catabolism of amino acids might
be more important to generate ATP and maintain cellular redox
state in nutrients limited condition.
In addition to the metabolism of carbohydrates and amino
acids, lipids can also be used as an important fuel to supplement
cancer cells proliferation requirements. Uptake of lipoproteins
and free fatty acids (FFAs) from the bloodstream is the main
source of satisfying lipid requirement in adult mammalian
tissues. Although, fatty acids biosynthesis is limited to a subgroup
of tissues, including adipose, liver and breast, reactivation of
lipid synthesis is commonly observed in tumor cells with
different sites of origin (Menendez and Lupu, 2007; Abramson,
2011). In vitro, glucose supplies significant amount of carbon
needed for the de novo synthesis of lipids, however, in hypoxic
condition or expression of oncogenic Ras, phospholipids uptake
can contribute to lipid pools, compensating decreased flux of
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glycolytic carbon through pyruvate dehydrogenase (Kamphorst
et al., 2013). Hypoxia may also change the fate of glutamine
entering mitochondria by preferring reductive carboxylation to
support tumor cell growth by activating fatty acid biosynthesis
(Metallo et al., 2012; Mullen et al., 2012). Recently, regardless
of relatively low levels in serum and culture media, acetate
was proposed as an important carbon source for fatty acid
biosynthesis and mitochondrial metabolism in hypoxic or
highly glycolytic tumors. Acetyl-CoA synthetase enzyme (ACSS1;
Björnson et al., 2015) and (ACSS2; Comerford et al., 2014; Schug
et al., 2015) plays a key role in cancer cell proliferation, by
capturing acetate and converting it to acetyl-CoA.
GENOME-SCALE MODELING OF CANCER
METABOLISM
Biological systems are complex interactive networks with
interconnected set of components (e.g., metabolites, proteins,
nucleic acids) and the function of the many different pathways
connecting these components is highly regulated. Mutations
may cause dysfunction of some of these regulatory or
functional pathways, and this may lead to the emergence of
dysfunctional phenotypes. Uncovering how these biological
systems orchestrate their activities to support specific phenotypic
transformation, e.g., normal to cancer, is a major challenge
in medical science, and gaining insight into the mechanisms
underlying these transformation may enable improved disease
diagnostic, prognostic, and treatment strategies (Hyduke et al.,
2013; Resendis-Antonio et al., 2015). Recent technological
breakthroughs in high-throughput omics techniques and
next generation sequencing (NGS) methods has transformed
biomedicine into a data-rich discipline capable of providing
deeper insights into phenotypic states of cells by simultaneous
measurement of a large number of cellular components.
However, analyzing very large sets of omics data with the
objective to extract new biological knowledge is not a trivial
effort. Despite this significant technological progress, we can
still only measure fluxes in eukaryote cells for a limited number
of reactions in central metabolism (Niklas et al., 2010). Systems
biology approach in general, and genome scale metabolic models
(GEMs) in particular, can facilitate this hurdle and bridge this
gap by allowing multi-layer integration of omics data in the
context of whole biological system (Mardinoglu and Nielsen,
2012; Mardinoglu et al., 2015; Yizhak et al., 2015). Furthermore,
GEMs enable simulation of multi-species relationships in
different metabolic states under dynamic environmental and
genetic perturbations (Oberhardt et al., 2009; Shoaie et al.,
2015; Zhang et al., 2015). In this context, GEMs are a powerful
framework to analyze omics data in health and disease states and
to investigate fundamental cellular mechanisms (Mardinoglu
and Nielsen, 2015).
Reconstruction of a GEM is performed by assembling
biochemical transformations, occurring within a specific cell
or tissue into the metabolic network (Thiele and Palsson,
2010; Mardinoglu and Nielsen, 2015). In GEMs the constructed
stoichiometry matrix of the network covers stoichiometric
coefficients of the metabolic reactions supplemented by detailed
mapping of the protein coding genes to their corresponding
reactions. In general, the metabolic networks are assumed to
be modeled in quasi-steady state, and reconstructed GEMs
are analyzed with constraint-based modeling (CBM) techniques
(Figure 2). CBM shapes feasible solution space by imposing
physico-chemical constraints, including thermodynamics, mass
balance, and minimum/maximum flux capacity boundaries.
The generated models usually remain under-determined, with
possible alternative flux distributions satisfying the constraints.
Flux balance analysis (FBA) method is used to formulate the
problem and select an optimal flux distribution by optimizing for
an objective function such as maximum biomass yield or ATP
production (Thiele and Palsson, 2010; Mardinoglu et al., 2013b;
Simeonidis and Price, 2015; Yizhak et al., 2015).
To date, a number of generic GEMs of human metabolism
including Recon1 (Duarte et al., 2007), Recon2 (Thiele et al.,
2013), HMR (Mardinoglu et al., 2013a), and HMR2 (Mardinoglu
et al., 2014) have been reconstructed (Duarte et al., 2007;
Thiele et al., 2013; Mardinoglu et al., 2013a, 2014). These
models represent an assembly of all reactions documented to
take place in metabolism of human cells/tissues integrated with
known genes catalyzing each reaction, and have been used to
generate context based GEMs of healthy human cells/tissues as
well as transformed cells. In recent years, availability of cancer
related high-throughput omics data made it possible to map
this data into the generic human GEMs and to reconstruct
cancer-specific genome-scale models. Several methods aiming
to acquire tissue-specific or condition-specific active metabolic
networks from a generic model have been developed. One
of the first attempts in this context was the Gene Inactivity
Moderated by Metabolism and Expression (GIMME) algorithm,
which uses mRNA expression data as input together with
presumed metabolic objectives to develop the context-specific
reconstructed models (Becker and Palsson, 2008). Shlomi et al.
(2008) proposed a computational method to generate tissue-
specific metabolic networks by integrating tissue-specific gene
and protein expression data with generic human genome-scale
metabolic network. Same authors developed another method
to reconstruct tissue-specific genome-scale metabolic models
by integrating transcriptomics, proteomics, metabolomics, and
phenotypic data. They use their method to reconstruct a
functional metabolic model of human hepatocytes (Jerby et al.,
2010).
Folger et al. (2011) has used a core set of 197 highly expressed
enzymes common to at least 90% of the cells in NCI-60 cell
lines database to generate a generic genome-scale metabolic
model of cancer. This model has been used to capture core
metabolic functions shared by cancer cell lines and to identify
potential anti-cancer drug targets (Folger et al., 2011). Moving
forward, Agren et al. (2012) reconstructed active metabolic
networks in genome-scale for 69 healthy and 16 cancer cell
types based on protein abundance data. A comparative analysis
of generated models allowed prediction of cancer-associated
metabolic features with potential to be used in identification
of novel drug targets (Agren et al., 2012). Similarly, Wang
et al. (2012) reconstructed GEMs for 26 human cancer and
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FIGURE 2 | Constraint-based modeling (CBM) and flux balance analysis (FBA). Genome-scale metabolic models have been constructed through
constraint-based modeling approach and analyzed following FBA method to find feasible flux distribution. (A) Conceptual illustration of simple metabolic network by
defining system boundaries, external/internal metabolites, exchange reactions, and internal reactions. (B) The stoichiometric matrix of the network is reconstructed to
formulate FBA model under steady-state condition. (C) Models is formulated by defining a biologically/context relevant objective function and introducing
physico-chemical constraints. (D) FBA provides an optimum feasible flux distribution relevant to defined objective function and compatible with enforced constraints.
counterpart normal tissues, inferring tissue-specific metabolic
models based on network topology and gene expression data.
Pathway-level analysis of GEMs revealed eicosanoid metabolic
pathway as a potential selective drug target (Wang et al., 2012).
Jerby et al. developed a method to infer metabolic phenotypes
by integrating transcriptomics and proteomics data derived
from breast cancer patients into the GEMs. They identified
a tradeoff linking decrease in tumor cells proliferation rate
to evolved metastatic ability, as well as, to increased need
for ROS detoxification (Jerby et al., 2012). Later, Goldstein
et al. in an attempt to identify the role of p53 in regulating
metabolic pathways, employed constraint-based modeling to
characterize metabolic changes imposed by varying p53 status
in human liver-derived tumor cells. Their results suggested that
p53 may regulate glucose metabolism by preventing it to be
shunted to growth promoting pathways such as glycolysis and
the pentose phosphate pathway (PPP) and therefore inhibiting
tumorigenesis (Goldstein et al., 2013). Feizi et al. used GEMs
generated based on NCI-60 cell lines database to identify growth-
associated metabolic sub-networks. They suggested critical role
of concurrent synthesis and degradation of lipids in supplying
energy for cell growth, and negative correlation of growth-
associated sub-networks with colon cancer patients’ survival
(Feizi and Bordel, 2013). In addition to the cancer specific
GEMs, Agren et al. (2014) reconstructed personalized cancer
GEMs for 27 hepatocellular carcinoma (HCC) patients and used
these models to predict 101 common and 46 patient-specific
potential antimetabolites that could inhibit tumor growth in
HCC patients. Recently, cell line-specific GEMs (CL-GEMs)
were developed and successfully employed to identify cell-level
metabolic phenotypes and selective drug targets (Yizhak et al.,
2014; Ghaffari et al., 2015). We recently generated CL-GEMs
for 11 human cancer cell lines with different site of origin
and used them to investigated expressional heterogeneity of
metabolic pathways across cancer cells. Furthermore, we used
CL-GEMs to identify antimetabolites aiming to simultaneous
inhibition ofmultiple growth supporting enzymes in proliferative
cells. We predicted 60 common and 15 cell/cell group-specific
potential antimetabolites and experimentally validated one of the
identified anti-growth factors.
These studies demonstrate the successful employment of
GEMs in deciphering metabolic foundations of neoplastic
phenotypes and identification of new selective biomarkers
and drug targets. Next generation of GEMs that integrate the
cell metabolism with regulation and signaling are crucial but
nontrivial challenge ahead, to tackle complexity of cancer
cell metabolism. Up to now, a couple of methods have been
developed to integrate the dynamic behavior of regulatory,
signaling and metabolic networks in prokaryotes, and single-cell
eukaryotes. The integrated FBA (iFBA) approach was used to
generate an integrated model of central carbon metabolism in
Escherichia coli by introducing ordinary differential equations
(ODEs) and regulatory Boolean logic into FBA (Covert et al.,
2008). Integrated dynamic FBA (idFBA) method proposed a
FBA-based framework by incorporating metabolic, regulatory,
and signaling processes through an integrated stoichiometric
formalism, assuming fast reactions in quasi-steady state
condition and introducing slow reactions in a time-delay
manner (Lee et al., 2008). idFBA was applied to evaluate the
phenotypic effects of environmental cues on Saccharomyces
cerevisiae. However, large number of parameters required to
be considered and accurate prediction of all the rate constants
for the regulatory and signaling pathways is a long-standing
challenge for this kind of approaches.
CANCER METABOLIC HETEROGENEITY,
TUMOR MICROENVIRONMENT, AND
SITE-OF-ORIGIN
The progressive accumulation of knowledge of cancer biology
has demonstrated that cancer is an extraordinarily heterogeneous
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and complex disease. Tumors evolve through a reiterative process
of clonal extension, genetic diversification and selection within
the highly dynamic and adaptive ecosystem of target tissue
(Greaves and Maley, 2012). Cancer cells rewire their metabolism
to satisfy demands of cell proliferation and survival within the
constantly changing tumor microenvironment (Hanahan and
Weinberg, 2011). Despite common tendency of cancer cells
toward uniformity of metabolism to support growth stimulating
adaptations, variable patterns of clonal architecture, genetic
diversity, and environmental effects results in a heterogeneous
metabolic signature of tumors (Greaves and Maley, 2012;
Meacham and Morrison, 2013). Apparently, a single model of
cancer metabolism cannot describe the diversity of metabolic
alterations happening during tumor progression. Differences
in tumor micro-environmental conditions and also nutrients
availability may constrain the potential metabolic repertoire
of the cancer cells. In vivo, nutrient availability varies for
different cell types, inside and across tissues/organs. For example,
the structure of liver enforces gradients of nutrients and
oxygen accessibility through hepatocyte zones (Puchowicz et al.,
1999). Considerable expressional variation has been observed
in cell cycle markers, together with association between oxygen
gradients and hypoxia-related gene expression in glioblastoma
cancer cells (Patel et al., 2014). Differences in active state of
pyruvate kinase have been associated with proliferating and non-
proliferating cell populations within breast cancer, revealing an
influence of glucose metabolism on tumor formation and growth
(Israelsen et al., 2013; Iqbal et al., 2014; Wong et al., 2015).
Comparing expressional patterns of metabolic genes from 22
different human tumor types demonstrated overall similarity of
gene expression program between tumors and corresponding
normal tissue (Hu et al., 2013). Reconstructed CL-GEMs for
11 human cancer cell lines have been employed to investigate
different mRNA expression pattern of metabolic pathways, and
this revealed expressional heterogeneity of metabolic pathways
across cancer types which can be exploited to identify generic
or cancer-specific metabolic targets (Ghaffari et al., 2015). Site-
of-origin may define the effect of oncogenic drivers in different
tissues, as Myc-driven lung and liver tumors display dissimilar
phenotypes related to glutamine metabolism (Yuneva et al.,
2012).
Tumor-host metabolic interactions also have strong effect
on the cancer cell metabolic reprogramming. Cancer cells
may attempt to induce growth favoring conditions by actively
manipulating the tumor microenvironment which can directly
influence tumor progression, metastasis, and redox status
(Guillaumond et al., 2013; Shukla et al., 2014). Metabolic
cooperation between intra-tumor cell populations can help
cancer cells to handle spatial heterogeneity of environmental
conditions and nutrients availabilities. It has been shown that
lactate out-flux by hypoxic pancreatic ductal adenocarcinoma
cells can fuel the growth of neighboring normoxic cancer
cells (Sonveaux et al., 2008; Guillaumond et al., 2013).
Better understanding of tumor metabolic heterogeneity and
tumor-host interactions has a high potential to optimize
therapeutic strategies for selectively targeting cancer. Moreover,
identification of the secreted proteins or peptides from cancer
cells which remodel the tumor microenvironment may allow
for discovery of novel cancer biomarkers and therapeutic targets
(Feizi et al., 2015).
CONCLUDING REMARKS
Cancer cells are shown to experience characteristic changes
in their metabolic programs, including increased uptake of
glucose, enhanced rates of glutaminolysis and fatty acids
synthesis, suggesting that metabolic shifts supports tumor cells
growth and survival. Similarity some cancer-associatedmetabolic
alterations are similar to the metabolic response of normal
cells to growth-promoting signals, and this makes it difficult
to separate neoplastic alterations clearly from the ones just
reflecting increased cellular proliferation. However, different
metabolic components target distinct oncogenic signaling
pathways, and it is therefore important to elucidate the complex
interaction between cellular metabolic network and oncogenic
signaling network. Obviously, transformation from oxidative
phosphorylation to aerobic glycolysis cannot simply explain the
complete metabolic reprogramming event of tumor cells, and
fairly little is known about different metabolic activities of cancer
cells with diverse genetic and mutational background. Moreover,
variances in metabolic profiles of tumors with same genetic
lesion but different tissues of origin, suggests an open therapeutic
window through investigation of complex metabolic interplay
between tumor cells and stroma. It is becomingmore evident that
metabolic reprogramming in cancer cells is closely connected to
hypoxia and ROS metabolism. Disrupting the balance between
anti-oxidant production and increased biosynthetic activities in
tumor cells seems to be a therapeutic opportunity.
Recent advances in high throughput omics technologies
along with continuous progress in our understanding of cancer
cell biology have portrayed a more complex and heterogeneous
picture of tumor metabolism. Increased understanding of genetic
and metabolic heterogeneity of cancer cells may open a new road
toward development of new selective personalized diagnostic
and therapeutic methods. GEMs, providing a mechanistic
description of relationships between genes, metabolites and
reactions within an interconnected functional metabolic
network, have potential to integrate large-scale experimental
datasets and extract knowledge out of their multi-dimensional
complexity. Despite recent leap forward in employing GEMs
to study cancer metabolism, more technical, and translational
challenges are laying ahead. To date, the majority of models
have been developed based on in vitro data that were produced
under experimentally controlled conditions, but utilization of
richer in vivo and clinical datasets, together with integration
of cellular regulatory and signaling mechanism is critical for
advancement of the field. Introduction of more metabolomics,
fluxomics and growth related data along with other related
omics data into the reconstruction and validation process
of GEMs can help in increasing the accuracy and prediction
power of these models. Furthermore, more and more data
points toward the important role of tumor microenvironment
in promoting plasticity and supporting cancer-associated
metabolic adaptations, and modeling metabolic interaction
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between cancer and its environment can help in developing
more effective therapeutic strategies. For this it may be
necessary to integrate kinetics into stoichiometric genome-scale
models.
In conclusion, metabolic reprogramming is crucial to support
the uncontrolled proliferation, survival and migration of cancer
cells, but at the same time renders tumors more vulnerable
to metabolic perturbations. Identification of these metabolic
dependencies at the genome-scale may provide an opportunity
for optimized therapeutic intervention.
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